| Autor: |
Ahsan M; Department of Pharmacology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia., Shaik RA; Department of Family & Community Medicine, College of Medicine, Majmaah University, Al Majmaah 11952, Saudi Arabia., Mallick AK; Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha 61421, Saudi Arabia., Banawas SS; Department of Medical Laboratories, College of Applied Medical Science, and Health and Basic Sciences Research Center, Majmaah University, Majmaah 11952, Saudi Arabia.; Departments of Biomedical Sciences and Microbiology, Oregon State University, Corvallis, OR 97331, USA., Alruwaili TAM; Department of Pediatrics, College of Medicine, Jouf University, Aljouf 72388, Saudi Arabia., Alanazi YA; Department of Pediatrics, College of Medicine, Majmaah University, Majmaah 11952, Saudi Arabia., Alzahrani HS; Department of Clinical Science, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia., Ahmad RK; Department of Physiotherapy, College of Applied Medical Science, Buraydah Private Colleges, Buraydah 51418, Saudi Arabia., Ahmad MS; Department of Family & Community Medicine, College of Medicine, Majmaah University, Al Majmaah 11952, Saudi Arabia., AlAnazi FH; Department of Medicine, College of Medicine, Majmaah University, Majmaah 11952, Saudi Arabia., Alfhaid F; Department of Family & Community Medicine, College of Medicine, Majmaah University, Al Majmaah 11952, Saudi Arabia., Aljulifi MZ; Department of Family & Community Medicine, College of Medicine, Majmaah University, Al Majmaah 11952, Saudi Arabia., Mehta V; Department of Public Health Dentistry, Dr.D.Y.Patil Dental College and Hospital, Dr.D.Y.Patil Vidyapeeth, Pune 411018, India., Almhmd AE; College of Medicine, Majmaah University, Majmaah 11952, Saudi Arabia., Daham ASDA; College of Medicine, Jouf University, Aljouf 72388, Saudi Arabia., Alruwaili MMM; College of Medicine, Jouf University, Aljouf 72388, Saudi Arabia. |
| Abstrakt: |
The objective of this study is to assess the frequency and severity of adverse events following immunization (AEFI) in Indian children aged 5-17 years who received the Pfizer-BioNTech mRNA COVID-19 vaccine, as well as to investigate for predictors of AEFI. To examine AEFI following the first and second doses of Pfizer's vaccine, semi-structured questionnaires were distributed as Google forms at Indian schools in Saudi Arabia. The 385 responses included 48.1% male and 51.9% female children, with 136 responses of children aged 5-11 years (group A) and 249 responses from children aged 12-17 years (group B). Overall, 84.4% of children had two shots. The frequency of AEFI was reported to be higher after the first dose than after the second (OR = 2.12, 95% CI = 1.57-2.86). The reported AEFIs included myalgia, rhinitis, local reaction with fever, a temperature of 102 °F or higher, and mild to moderate injection site reactions. While group B frequently reported multiple AEFIs, group A typically reported just one. Local reaction with low grade fever was more frequently reported in group B after the first dose (24.1%) and second dose (15.4%), while local reaction without low grade fever was most frequently observed in group A after the first (36.8%) and second dose (30%). Only prior COVID-19 infection (OR = 2.98, 95% CI = 1.44-6.2) was associated with AEFI after the second dose in the study sample, whereas male gender (OR = 1.71, 95% CI = 1.13-2.6) and prior COVID-19 infection (OR = 2.95, 95% CI = 1.38-6.3) were predictors of AEFI after the first dose. Non-serious myocarditis was reported by only one child. According to the analysis conducted, the Pfizer's mRNA COVID-19 vaccination was found to be safe in Indian children. |
